Condition
Crohn's disease news across medications, symptoms, tests, procedures, complications, research, access, and daily life.
Page 21 of 53 · 2520 articles
New investigational therapy AZD7798 is being tested specifically for mucosal repair in people with active ileal Crohn’s disease who have an ileostomy — a group often excluded from other trials. Trial results could be...
This trial could show whether intra-operative ultrasound can be used reliably to choose the proximal resection margin during ileocecal resection for terminal ileal Crohn’s disease—information that might affect surgical...
Cure8 found this source from marketscreener.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Risankizumab. Open the original article for the full...
Cure8 could only read part of this source from app.dealroom.co, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Stricture.
Obesity is increasingly common in people with IBD and can affect disease course, treatment response, and surgical risk.
Fatigue is very common in people with IBD—even when the disease is in remission—and is linked with lower physical activity, more sitting time, and with anxiety/depression. Understanding these links may help patients and...
Fundraisers like this support research, patient programs, and advocacy that can expand resources and advance scientific work relevant to people with Crohn’s disease and ulcerative colitis.
Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Risankizumab. The original article is from tradingview.com.
Cure8 could only read part of this source from marketscreener.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Risankizumab.
A subcutaneous induction option could make starting risankizumab easier and less burdensome than IV infusions for many people with Crohn's disease, potentially expanding access and convenience.
Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Risankizumab, and IL-23 inhibitor. The original article is from msn.com.
A new subcutaneous induction option for risankizumab could make starting IL‑23 therapy more convenient for adults with moderately to severely active Crohn’s disease and expand choices for those who have failed prior...
If approved, a subcutaneous induction option for risankizumab would let eligible adults start and continue treatment without needing an infusion visit, which can be more convenient and reduce infusion-related costs and...
This bill could make lower-cost biosimilars more available at the pharmacy counter, potentially reducing out-of-pocket costs and helping people with Crohn’s disease and other conditions stay on prescribed biologic...
The story connects an artist’s recovery from Crohn’s-related complications to his creative work and fundraising for the Crohn’s & Colitis Foundation, which may resonate with people living with IBD and supporters.
Pediatric IBD affects growth, nutrition, puberty, and long-term quality of life, so families and clinicians need to recognize its broader impacts and the importance of coordinated multidisciplinary care.
Diet quality was linked to gut microbiome features and exploratory differences in inflammatory markers and symptoms in adults with Crohn disease from Puerto Rico; understanding these links may help tailor dietary...
Patients and clinicians may notice fewer resources from a major drugmaker focused on a specific T‑cell antigen discovery effort for Crohn’s disease; researchers and investors should see this as a signal about how large...
Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Community and awareness. The original article is from msn.com.
News about large drugmakers’ pipelines and analyst optimism can affect future availability and development of therapies for IBD. Mentions of a drug (Tulisokibart) being developed for ulcerative colitis and Crohn’s may...
This research suggests a new way the gut could “remember” prior injury: lasting changes in the tissue scaffold (ECM) that may push stem cells toward pro‑inflammatory behavior and help explain recurring IBD flares.
The study points to CD226 (DNAM-1) being linked to inflammatory and interferon-driven programs in specific intestinal immune cells in Crohn's disease, which may be relevant to understanding disease mechanisms or...
Patients, clinicians, and payers may care because the analysis addresses the relative economic value of two approved biologic options (vedolizumab and risankizumab) for Crohn’s disease treatment in Italy and could...
Because having a sibling with Crohn's disease during childhood was linked to substantially higher risk of developing Crohn's later, and the study points to early-life microbiome differences and elevated faecal...
Non-invasive, inexpensive blood-derived ratios could offer easier, more frequent assessment of IBD activity than repeat endoscopy. This study evaluates several such ratios (CAR, PAR, NLR, FAR, Hb/CRP) against clinical...
Perianal fistulizing Crohn’s disease is difficult to treat and many patients don’t respond to available medical and surgical options. This trial tests an existing wound‑healing therapy (HBOT) in a formal controlled...
Researchers and patients tracking new IBD therapies may care because this is the first human study of a GlaxoSmithKline investigational drug aimed at colitis/ulcerative colitis — an early step that could lead to future...
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Fecal calprotectin, and Fistula. The original article is from Colorectal Disease.
Cardiovascular disease is an important nonintestinal complication for people with IBD; knowing if heart failure risk differs by IBD type could influence monitoring and care planning.
Fistulizing Crohn’s disease is a major complication where durable structural repair is hard to achieve. Regenerative cell-sheet approaches aim to rebuild tissue architecture rather than only suppress inflammation, which...
Time-restricted eating could offer a nonpharmacologic way to improve weight and some metabolic measures, and an early small study suggests it might reduce some Crohn’s symptoms in people who are overweight and in...
The FDA label clarifies that ZYMFENTRA (a TNF blocker) is indicated for maintenance treatment of moderate–severe Crohn’s disease and ulcerative colitis after prior infliximab, and it carries strong safety warnings...
Delays in diagnosing IBD are common and can raise the risk of complications, so understanding when to push for testing matters. The article explains tests and differences between IBS and IBD to help people know when to...
Cure8 could only read part of this source from tradingview.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Access, cost, and policy.
A local athlete’s story shows how Crohn’s disease can be managed while pursuing competitive goals and advocacy; it may encourage others with IBD who face fatigue, pain, or diet-related triggers.
The study suggests that modifiable early-life factors (feeding, antibiotic exposure, activity, BMI, smoke exposure, delivery mode, diet) may influence the later risk of IBD, especially Crohn's disease, which could be...
Based on the title and source metadata, this appears to be a case report related to Crohn's disease, Strictureplasty, and Procedures and surgery. The original article is from Updates in surgery.
A validated claims-based algorithm could enable larger, more efficient studies of fibrostenosis in Crohn’s disease using real-world data — helping researchers and clinicians better measure how often stricturing...
Researchers are exploring ways to prioritize who needs colonoscopy sooner; adding TCM features to prediction models might change triage performance. Patients and clinicians interested in pre-endoscopic risk tools or...
This story highlights how hospital billing, administrative errors, and gaps in hospital care (privacy, dietary needs) can create financial and emotional stress for people with Crohn’s disease. It underscores broader...
Endometriosis may coexist with IBD and can cause pelvic pain, painful sex, and heavy periods—symptoms that may be mistaken for bowel disease activity. Identifying endometriosis could change evaluation and management for...
This work suggests that non-immune stromal cells can hold an epigenetic ‘memory’ that keeps intestinal tissue in a disease-promoting state, which may help explain relapse or incomplete responses to immune-focused...
TL1A-DR3 is implicated in both inflammation and fibrosis in IBD, so targeting it could address active disease and reduce fibrotic complications that lead to strictures. New TL1A-blocking antibodies are already in...
The study links a polyphenol-rich diet to a specific microbiome change and a microbial metabolite (4-HPAA) that reduced inflammation in mouse models — offering a possible mechanism by which diet could influence Crohn's...
Delays in diagnosis and restricted access to therapies can allow Crohn’s inflammation to progress, increasing the chance of bowel damage and worse outcomes. Progress on earlier detection and better matching of treatments...
Intestinal ultrasound provides a noninvasive, real-time way to see bowel inflammation and may reveal treatment response earlier than symptoms alone. That can help clinicians make timely treatment changes to prevent...
These development programs could expand treatment choices for Crohn’s disease and may eventually address fibrosis and refractory disease—two major unmet needs. Progress in trials could change management options in coming...
Based on the title and source metadata, this appears to be a case report related to Crohn's disease, Inflammatory bowel disease, and Fistula. The original article is from cureus.com.
